Tradestie Institutional Equity Comparison Engine
IBD vs BLES โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BLES Overall Edge
BLES Captures Institutional Edge (1โ0 Pillars ยท 2โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Inspire Global Hope ETF (BLES) driven by superior Momentum & Technical. Fundamentally, IBD trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus BLES at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, IBD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BLES sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
IBD N/M vs BLES N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner
BLES
1Y -4.4% vs +11.4% ยท 52W Pos 26% vs 68%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
IBD
NYSE Arca
Inspire Corporate Bond ETF
Institutional Equity
$23.10
-0.04% 1D
Market Cap
N/A
1M Return
-0.56%
1Y Return
-4.39%
Forward P/E
N/M
Unified AI Score
44.1 / 100
HOLD
Tech 49.0
Fund 51.0
Flow 50.0
Mom 54.0
BLES
NYSE Arca
Inspire Global Hope ETF
Institutional Equity
$47.47
-2.18% 1D
Market Cap
N/A
1M Return
+0.19%
1Y Return
+11.41%
Forward P/E
N/M
Unified AI Score
52.9 / 100
HOLD
Tech 48.0
Fund 54.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
IBD -4.39%
BLES +11.41%
Spread: +15.8 pp (BLES Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
IBD TTM Op. Margin: N/A
BLES TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBD vs BLES. Trailing 12-month operating profitability (IBD N/A vs BLES N/A) and valuation multiples (IBD N/M vs BLES N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IBD | BLES | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | N/A | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | N/A | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | N/A | N/A | Higher Margin | Tie |
| Net Profit Margin Profitability | N/A | N/A | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | N/A | N/A | Higher ROE | Tie |
| 52-Week Range Position Momentum | 26% ($22โ$25) | 68% ($41โ$50) | Stronger Trend | BLES |
| Beta / 30D Volatility Risk Regime | 0.11ฮฒ ยท 5% Vol | 0.80ฮฒ ยท 17% Vol | Lower Realized Risk | IBD |
| Unified Institutional Score Composite Signal | 44.1 / 100 (HOLD) | 52.9 / 100 (HOLD) | Higher Composite | BLES |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full IBD vs BLES Buy Guide
IBD
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
BLES
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither IBD nor BLES registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.